• Our Company
  • Our Science
  • Our Products
  • Join Us
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources
Kodiak Sciences
  • Our Company
  • Our Science
  • Our Products
  • Join Us
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor Resources

Pushing the boundaries

At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness

ABC Platform

We are advancing a portfolio of retina medicines built on our innovative antibody biopolymer conjugate platform that has been precision engineered over 10 years

Generation 2.0 Retinal Medicines

Antibody biopolymer conjugates are intended to be:

Same Where It Matters

  • Clinically proven targets
  • Antibody-based biologic
  • Intravitreal: safest method of administration
  • Optically clear, no residues
  • Fast and potent clinical responses

Different Where It Counts

  • Designed-in ocular durability
  • Designed-in rapid systemic clearance
  • Improved bioavailability
  • Improved biocompatibility
  • Improved stability

Go Big, Not Small

Size

In general, the larger the size, the longer the molecule will remain in the eye.

Drug per dose

Drug per dose is how many target binding units fit into the injected clinical dose.

Ocular half-life

Ocular half-life is how long the drug lasts in the eye which is a key driver of durability.

More than the sum of its parts

The ABC Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit

Remarkable Intraocular Half-life
Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentration levels in the eye

 

Excellent Retinal Bioavailability
The ABC Platform improves therapeutic absorption and distribution in the eye

Fast Systemic Clearing
The ABC Platform is designed to clear the body quickly after it exits from the eye

Take a 3-Dimensional Tour

Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360o below.

Click and drag to see different views. Scroll or pinch to zoom.

Kodiak Bioconjugate
by kodiaksciencesinc
on Sketchfab

Please be patient while the 3-D model loads

REVOLUTIONIZING TREATMENT OF MULTIFACTORIAL RETINAL DISEASES WITH TRIPLET MEDICINES

Our triplet medicines combine the benefits of our ABC platform with the sustained release of small molecules to target three mechanisms of action enabling treatment of complex diseases such as dry AMD

+

Bispecific antibody conjugated to phosphorylcholine biopolymer designed for improved ocular durability, excellent retinal bioavailability, and rapid systemic clearance

=

Small-molecule drug is embedded and attached into the phosphorylcholine biopolymer and designed for high biocompatibility, high drug loading, and sustained release

An amazing new single molecule drug format designed for retinal diseases to modulate multiple intracellular and extracellular disease pathways

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

Kodiak Sciences INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter
Copyright © 2021 Kodiak Sciences Inc.